Insulet Corporation filed a Form 8-K on November 20, 2026, disclosing that its Board of Directors appointed Michael R. Minogue as a Class I director, effective November 20, 2026, following his earlier resignation in September 2026.
Key Highlights
- Reappointment: Michael R. Minogue was appointed to Insulet's Board of Directors effective November 20, 2026, with his term set to expire at the Company's 2029 Annual Meeting of Stockholders.
- Prior service: Minogue previously served as a Class I director from August 2017 until September 2026, when he resigned to focus on his candidacy for Governor of Massachusetts.
- Initial equity grant: As a non-employee director, Minogue will receive an initial grant of restricted stock units with a grant date fair value of approximately $121,700, representing the pro-rated value of the $260,000 annual equity award under the Company's non-employee director compensation program.
- Professional background: Minogue served as Chairman, President, and CEO of Abiomed, Inc. from 2004 until its sale in December 2022, and previously spent 11 years with General Electric Healthcare.
- No related-party arrangements: The filing states there are no arrangements or understandings between Minogue and any other persons related to his selection, and no transactions requiring disclosure under Item 404(a) of Regulation S-K.
Insulet Board Reappoints Minogue After September 2026 Resignation
According to the filing, Insulet Corporation's Board of Directors voted on November 19, 2026 to reappoint Michael R. Minogue as a Class I director, with the appointment taking effect on November 20, 2026. Minogue had originally served on the Board from August 2017 until September 2026, when he stepped down to pursue a gubernatorial campaign in Massachusetts. His new term as Class I director will run through the Company's 2029 Annual Meeting of Stockholders.
The filing describes Minogue as President and CEO of Minogue Consulting, LLC and Heartwork Capital, LLC, providing leadership development programs, speaking engagements, mentoring, and investment in medical companies. Prior to those roles, he led Abiomed, Inc. as Chairman, President, and CEO from 2004 until its sale in December 2022. Before Abiomed, the filing notes he held numerous leadership roles over 11 years at General Electric Healthcare and holds three patents. He also served as Chairman of the Advanced Medical Technology Association (AdvaMed) from 2021 to 2023.
As compensation for his board service, the filing discloses that Minogue will receive an initial restricted stock unit grant with a grant date fair value of approximately $121,700. This figure represents the pro-rated portion of the $260,000 annual equity award provided under Insulet's non-employee director compensation program. Cash compensation will follow the program as described in the Company's proxy statement filed with the SEC on April 6, 2026, as the Board may amend it from time to time. The filing was signed by John W. Kapples, Senior Vice President and General Counsel, on behalf of Insulet Corporation (NASDAQ:PODD).
What Was Disclosed
Insulet Corporation disclosed the reappointment of Michael R. Minogue to its Board of Directors as a Class I director, effective November 20, 2026, including details of his compensation arrangement, professional background, and the absence of any related-party arrangements connected to his selection.




Please wait processing your request...